Rafferty Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Rafferty Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Sell	55,580 -47,161	-46%	-$1.43M	﹤0.01%	634
2026 Q1	$3.48M	Sell	102,741 -4,749	-4%	-$135K	0.01%	489
2025 Q4	$2.93M	Buy	107,490 +39,270	+58%	+$1.38M	0.01%	566
2025 Q3	$2.74M	Buy	68,220 +18,817	+38%	+$708K	0.01%	567
2025 Q2	$1.64M	Sell	49,403 -44,224	-47%	-$1.34M	0.01%	656
2025 Q1	$2.74M	Buy	93,627 +23,314	+33%	+$773K	0.01%	495
2024 Q4	$2.31M	Sell	70,313 -19,185	-21%	-$901K	0.01%	609
2024 Q3	$3.98M	Buy	89,498 +12,645	+16%	+$574K	0.01%	470
2024 Q2	$3.31M	Sell	76,853 -144,356	-65%	-$5.21M	0.01%	507
2024 Q1	$6.47M	Buy	221,209 +67,724	+44%	+$1.81M	0.02%	407
2023 Q4	$3.42M	Buy	153,485 +19,861	+15%	+$445K	0.01%	524
2023 Q3	$3.31M	Sell	133,624 -29,983	-18%	-$793K	0.02%	479
2023 Q2	$4.63M	Sell	163,607 -42,538	-21%	-$1.06M	0.03%	432
2023 Q1	$4.74M	Sell	206,145 -5,512	-3%	-$146K	0.03%	395
2022 Q4	$5.94M	Buy	211,657 +75,665	+56%	+$2.13M	0.05%	343
2022 Q3	$3.85M	Buy	135,992 +16,734	+14%	+$449K	0.04%	379
2022 Q2	$2.64M	Sell	119,258 -58,601	-33%	-$1.32M	0.02%	411
2022 Q1	$5.18M	Sell	177,859 -413	-0.2%	-$12.6K	0.03%	385
2021 Q4	$5.86M	Buy	178,272 +109,293	+158%	+$4.4M	0.03%	316
2021 Q3	$3.18M	Buy	68,979 +23,800	+53%	+$1.15M	0.02%	444
2021 Q2	$2.49M	Sell	45,179 -19,400	-30%	-$1.08M	0.02%	602
2021 Q1	$3.33M	Buy	64,579 +36,924	+134%	+$1.83M	0.02%	421
2020 Q4	$1.2M	Sell	27,655 -26,016	-48%	-$1.03M	0.01%	467
2020 Q3	$1.88M	Buy	53,671 +33,414	+165%	+$1.46M	0.02%	435
2020 Q2	$1.08M	Buy	20,257 +13,251	+189%	+$614K	0.02%	520
2020 Q1	$249K	Sell	7,006 -52,449	-88%	-$2.42M	0.01%	479
2019 Q4	$2.84M	Sell	59,455 -56,518	-49%	-$2.14M	0.04%	235
2019 Q3	$3.76M	Buy	115,973 +25,678	+28%	+$1.06M	0.06%	191
2019 Q2	$4.5M	Buy	90,295 +22,307	+33%	+$1.19M	0.08%	183
2019 Q1	$4.58M	Buy	+67,988	New	+$3.96M	0.07%	150

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Rafferty Asset Management's AGIO Position: Q2 2026 in Review

Rafferty Asset Management reduced its Agios Pharmaceuticals (AGIO) stake by 46% in Q2 2026, selling an estimated $1.43M and leaving 55,580 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #634.

Rafferty Asset Management first reported a position in AGIO in Q1 2019 and has held it in 30 quarters since. The position peaked at $6.47M in Q1 2024. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Rafferty Asset Management held 55,580 shares of Agios Pharmaceuticals worth $2.06M as of Q2 2026.
Rafferty Asset Management sold 47,161 Agios Pharmaceuticals shares in Q2 2026, an estimated $1.43M.
Agios Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #634 holding.
Rafferty Asset Management first reported a position in Agios Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
Rafferty Asset Management's Agios Pharmaceuticals position peaked at $6.47M in Q1 2024.
239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.